In late 2023, the agency recommended healthcare workers stop using plastic syringes made in China-based facilities because of new dimensions, which customers said were linked to leaks and breaks. On March 19, the FDA confirmed the issue, alerting clinicians the problem is “more widespread than originally known.”
The FDA issued warnings to two distributors and one manufacturer in China for allegedly selling unauthorized syringes.
The U.S. supply of plastic syringes is sufficient without these products, so a shortage is unlikely, the agency said. Nevertheless, BD began manufacturing more syringes at its Nebraska and Connecticut facilities, the company said in a March 21 news release.
BD said the FDA’s notification does not include its syringes, but it has the capacity to meet higher demand for syringes.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
